Brokerage firm Oppenheimer Maintains its rating on ANI Pharmaceuticals Inc(NASDAQ:ANIP). In a research note issued to the investors, the brokerage major Raises the price-target to $71.00 per share. The shares have been rated Outperform. The rating by Oppenheimer was issued on Aug 5, 2016.
In a different note, On Jul 19, 2016, Oppenheimer said it Upgrades its rating on ANI Pharmaceuticals Inc. The shares have been rated ‘Perform’ by the firm. Raymond James said it Initiates Coverage on ANI Pharmaceuticals Inc, according to a research note issued on Jun 23, 2016. The shares have been rated ‘Strong Buy’ by the firm. On May 24, 2016, Standpoint Research said it Downgrades its rating on ANI Pharmaceuticals Inc. The shares have been rated ‘Hold’ by the firm.
ANI Pharmaceuticals Inc (ANIP) shares turned negative on Wednesdays trading session with the shares closing down -0.61 points or -0.88% at a volume of 1,29,374. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $69.25. The peak price level was also seen at $69.25 while the days lowest was $68.05. Finally the shares closed at $68.68. The 52-week high of the shares is $70.92 while the 52-week low is $26.8. According to the latest information available, the market cap of the company is $791 M.
ANI Pharmaceuticals Inc(ANIP) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $31.33M. Analysts had an estimated revenue of $27.50M. Earnings per share were $1.11. Analysts had estimated an EPS of $0.80.
Several Insider Transactions has been reported to the SEC. On Dec 22, 2015, James G. Marken (Vice President, Operations) sold 3,500 shares at $43.26 per share price.Also, On Nov 12, 2015, Arthur Przybyl (CEO) purchased 2,500 shares at $40.95 per share price.On Mar 16, 2015, Tracy Marshbanks (director) sold 210,000 shares at $63.00 per share price, according to the Form-4 filing with the securities and exchange commission.
ANI Pharmaceuticals Inc. (ANI) is an integrated specialty pharmaceutical company engaged in developing manufacturing and marketing branded and generic prescription pharmaceuticals. The Company’s focused areas of product development include narcotics oncolytics (anti-cancers) hormones and steroids and complex formulations involving release and combination products. The Company has two pharmaceutical manufacturing facilities located in Baudette Minnesota that are capable of producing oral solid dose products as well as liquids and topicals narcotics and potent products. The Company’s branded products consist of Cortenema Lithobid Reglan and Vancocin. Its generic products include Esterified Estrogen with Methyltestosterone Fluvoxamine Maleate Hydrocortisone Enema Methazolamide Metoclopramide and Opium Tincture. The Company’s markets include hormone and steroidal drugs oncolytics and narcotics and complex formulations including extended release and combination products.